Reading MASI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MASI free→Reading MASI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MASI free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, while risk is moderate and the sector backdrop is a headwind. Peer multiples imply a price about 51% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. Key factors to watch include any potential guidance cuts from MASI and the performance of sector bellwethers like ABT, SYK, and MDT. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $179.95. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $180 the market pays 36× p/e — above the 23× p/e peer median but in line with its own 36× history. That premium reflects a durable franchise our peer-anchored $118 fair value understates; treat the 'expensive vs peers' read with medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 52% near-term growth, well above our forecast of about 0%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 3.04x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.12 → $1.00 (-10.7% / 30d). 2 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 0% of analysts rate Buy.
1 positive, 3 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$8.
How much price usually moves either way.
On a bad day, this stock has moved -$247.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,564.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Maintaining strong revenue growth supports Masimo's growth strategy. It shows the company is on track.
Confirms:Revenue reported above $403.6M in the next earnings report.
Disproves:Revenue below $372M shows growth is slowing down.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MASI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
On the day prior to the Closing Date, the Company notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of the expected consummation of the Merger and requested that Nasdaq file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 the next day with respect to delisting and deregistering the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). The Common Stock ceased trading prior to the opening of the market on the Clo…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MASI Masimo | Typical Show detailsSector percentile: 43 of 100 | expensive | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the acquisition of Danaher to enhance Masimo's growth and market position.
Focus on strategies to drive revenue growth across Masimo's product lines.
Enhance gross profit margins through operational efficiencies and cost management.
Why it matters: Revenue growth below 10% would signal a slowdown in the company's performance. This could impact investor confidence.
Confirms:Q3 revenue growth reported below 10% year over year.
Disproves:Q3 revenue growth remains at or above 10% year over year.
Why it matters: Higher gross profit margins show better cost control and profit. This may help investor feelings.
Confirms:Gross profit margins are higher than last quarter.
Disproves:Gross profit margins decline or remain flat compared to the previous quarter.
Why it matters: Better margins mean better cost control. This is important for making money long-term.
Confirms:Gross profit margins reported above the previous $250.8M in the next earnings report.
Disproves:Gross profit margins decline or stay below $250.8M, indicating cost issues.
Why it matters: A drop in sector growth could impact Masimo's performance. It signals broader industry challenges.
Confirms:Sector revenue growth below average shows a slowdown.
Disproves:Sector revenue growth stays steady or gets better, helping Masimo grow.
Why it matters: Revenue growth shows how well the company adapts after the merger.
Confirms:Q2 2026 revenue growth exceeds 10% year over year.
Disproves:Q2 2026 revenue growth falls below 5% year over year.
As a result of the Merger, at the Effective Time, a change in control of the Company occurred and the Company became a wholly owned subsidiary of Parent. Parent funded the acquisition with cash on hand.
Pursuant to the Merger Agreement, at the effective time of the Merger (the “ Effective Time ”), each share of common stock, par value $0.001 per share (“ Common Stock ”), of the Company (each, a “ Share ”) issued and outstanding immediately prior to the Effective Time (other than any (i) Shares owned by Parent, Merger Sub or the Company, (ii) Shares owned by any wholly owned subsidiary of Parent (other than Merger Sub) or any wholly owned subsidiary of the Company and (iii) Shares in respect…
In connection with the Merger, as of the Effective Time, (i) Catherine Szyman, Michelle Brennan, Quentin Koffey, Wendy Lane, Tim Scannell, and Darlene Solomon each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company, (ii) the director of Merger Sub (Frank McFaden) immediately prior to the Effective Time became the director of the Surviving Corporation, and (iii) except as described below eac…
Termination of a Material Definitive Agreement. In connection with the consummation of the Merger, on the Closing Date, the Company paid off all obligations owing, and terminated the commitments, under that certain Credit Agreement, dated as of December 1, 2025, by and among the Company, the lenders and issuing banks party thereto and Bank of America, N.A., as administrative agent (the “ Credit Agreement ”). In connection with the termination of the Credit Agreement, on the Closing Date, all…